Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic lymphocytic leukemia (CLL), but continuous therapy has been complicated by the development of resistance. The most common resistance mechanism in patients whose disease progresses on covalent BTK inhibitors (...

Descripción completa

Detalles Bibliográficos
Autores principales: Naeem, Aishath, Utro, Filippo, Wang, Qing, Cha, Justin, Vihinen, Mauno, Martindale, Stephen, Zhou, Yinglu, Ren, Yue, Tyekucheva, Svitlana, Kim, Annette S., Fernandes, Stacey M., Saksena, Gordon, Rhrissorrakrai, Kahn, Levovitz, Chaya, Danysh, Brian P., Slowik, Kara, Jacobs, Raquel A., Davids, Matthew S., Lederer, James A., Zain, Rula, Smith, C. I. Edvard, Leshchiner, Ignaty, Parida, Laxmi, Getz, Gad, Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202739/
https://www.ncbi.nlm.nih.gov/pubmed/36287227
http://dx.doi.org/10.1182/bloodadvances.2022008447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202739/
https://www.ncbi.nlm.nih.gov/pubmed/36287227
http://dx.doi.org/10.1182/bloodadvances.2022008447

Ejemplares similares